Scotiabank analyst Mike Rizvanovic maintains Manulife Financial (TSX:MFC) with a Sector Outperform and raises the price target from C$55 to C$56.
Merck, Ridgeback Biotherapeutics Highlights ‘New England Journal Of Medicine’ Published Findings From Phase 3 MOVe-OUT Trial Evaluating Molnupiravir In Non-Hospitalized High Risk Adults With Mild To Moderate COVID 19
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the New England Journal of Medicine has published findings from the Phase 3 MOVe-OUT trial evaluating
